Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples

Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertini...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Kiura, Katsuyuki, Yoh, Kiyotaka, Katakami, Nobuyuki, Nogami, Naoyuki, Kasahara, Kazuo, Takahashi, Toshiaki, Okamoto, Isamu, Cantarini, Mireille, Hodge, Rachel, Uchida, Hirohiko
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891183/
https://ncbi.nlm.nih.gov/pubmed/29363250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13511
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares